{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:23:43Z","timestamp":1791217423228,"version":"4.1.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1097\/cco.0b013e3282efb9da","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T18:40:40Z","timestamp":1236192040000},"page":"573-578","source":"Crossref","is-referenced-by-count":48,"title":["Flavopiridol in the treatment of chronic lymphocytic leukemia"],"prefix":"10.1097","volume":"19","author":[{"given":"Beth A","family":"Christian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Grever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0145-2126(99)00122-8","article-title":"Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia: the role of Bcl-2 family dysregulation","volume":"23","author":"Pepper","year":"1999","journal-title":"Leuk Res"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","article-title":"Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses","volume":"91","author":"Kitada","year":"1998","journal-title":"Blood"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood.V82.11.3452.3452","article-title":"p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1\/MDR3 gene expression","volume":"82","author":"El Rouby","year":"1993","journal-title":"Blood"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","article-title":"p53 mutations are associated with resistance to chemotherapy and short survival in hematologic maligancies","volume":"84","author":"Wattel","year":"1994","journal-title":"Blood"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1182\/blood.V91.11.4342","article-title":"p53 expression in B-cell chronic lymphocytic leukemia: a marker for disease progression and poor prognosis","volume":"91","author":"Cordone","year":"1998","journal-title":"Blood"},{"issue":"Suppl","key":"R7-6-20210128","first-page":"1","article-title":"Genomic aberrations, p53 abnormalities, and IgV mutation: relationship to disease evolution, resistance to therapy, and clinical course of CLL","volume":"42","author":"Stilgenbauer","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood.V106.11.715.715","article-title":"17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG [abstract]","volume":"106","author":"Stilgenbauer","year":"2005","journal-title":"Blood"},{"key":"R10-6-20210128","first-page":"1938","article-title":"ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and AT heterozygotes","volume":"82","author":"Delia","year":"2000","journal-title":"Br J Cancer"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/sj.onc.1203444","article-title":"Ionizing radiation activates the ATM kinase throughout the cell cycle","volume":"19","author":"Pandita","year":"2000","journal-title":"Oncogene"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1126\/science.281.5383.1677","article-title":"Activation of the ATM kinase by ionizing radiation and phosphorylation of p53","volume":"281","author":"Canman","year":"1998","journal-title":"Science"},{"key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0014-5793(00)01422-8","article-title":"Protective roles for ATM in cellular response to oxidative stress","volume":"472","author":"Takao","year":"2000","journal-title":"FEBS Lett"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/emboj\/19.3.463","article-title":"The controlling role of ATM in homologous recombinational repair of DNA damage","volume":"19","author":"Morrison","year":"2000","journal-title":"EMBO J"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0140-6736(98)10117-4","article-title":"Inactivation of ataxia telengiectasia mutated gene in B-cell chronic lymphocytic leukaemia","volume":"353","author":"Stankovic","year":"1999","journal-title":"Lancet"},{"key":"R16-6-20210128","first-page":"24","article-title":"ATM mutations in B-cell chronic lymphocytic leukemia","volume":"59","author":"Bullrich","year":"1999","journal-title":"Cancer Res"},{"key":"R17-6-20210128","first-page":"4552","article-title":"Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia","volume":"58","author":"Starostik","year":"1998","journal-title":"Cancer Res"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.V94.2.748","article-title":"Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia","volume":"94","author":"Schaffner","year":"1999","journal-title":"Blood"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood.V98.3.814","article-title":"p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation","volume":"98","author":"Pettitt","year":"2001","journal-title":"Blood"},{"key":"R20-6-20210128","first-page":"36","article-title":"Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab","volume":"63","author":"Byrd","year":"2003","journal-title":"Cancer Res"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"key":"R22-6-20210128","first-page":"771a","article-title":"Campath-1H in refractory CLL: complete remission despite p53 gene mutation","volume":"98","author":"Stilgenbauer","year":"2001","journal-title":"Blood"},{"key":"R23-6-20210128","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"N Engl J Med"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood.V104.11.478.478","article-title":"Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG) [abstract]","volume":"104","author":"Stilgenbauer","year":"2004","journal-title":"Blood"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-003-0710-5","article-title":"High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities","volume":"82","author":"Thornton","year":"2003","journal-title":"Ann Hematol"},{"key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1749-6632.2000.tb06710.x","article-title":"Inhibition of CDKs as a therapeutic modality","volume":"910","author":"Sausville","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R27-6-20210128","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/92.5.376","article-title":"Preclinical and clinical development of cyclin-dependent kinase modulators","volume":"92","author":"Senderowicz","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R28-6-20210128","first-page":"2973","article-title":"Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells","volume":"56","author":"Carlson","year":"1996","journal-title":"Cancer Res"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/jnci\/84.22.1736","article-title":"Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275","volume":"84","author":"Kaur","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/0006-2952(93)90590-S","article-title":"Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: correlation with decreased H1 kinase activity","volume":"46","author":"Worland","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V96.2.393","article-title":"Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia","volume":"96","author":"Kitada","year":"2000","journal-title":"Blood"},{"key":"R32-6-20210128","first-page":"3527","article-title":"The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1","volume":"8","author":"Gojo","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R33-6-20210128","doi-asserted-by":"crossref","first-page":"0041.1","DOI":"10.1186\/gb-2001-2-10-research0041","article-title":"Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anticancer drug flavopiridol","volume":"2","author":"Lam","year":"2001","journal-title":"Genome Biol"},{"key":"R34-6-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1097-2765(03)00526-4","article-title":"Coordination of transcription, RNA processing, and surveillance by TEFb kinase on heat shock genes","volume":"13","author":"Ni","year":"2004","journal-title":"Mol Cell"},{"key":"R35-6-20210128","doi-asserted-by":"crossref","first-page":"31793","DOI":"10.1074\/jbc.M102306200","article-title":"Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo","volume":"276","author":"Chao","year":"2001","journal-title":"J Biol Chem"},{"key":"R36-6-20210128","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804.422k36_3804_3816","article-title":"Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53","volume":"92","author":"Byrd","year":"1998","journal-title":"Blood"},{"key":"R37-6-20210128","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood.V91.2.458","article-title":"Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol","volume":"91","author":"Parker","year":"1998","journal-title":"Blood"},{"key":"R38-6-20210128","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1200\/JCO.1998.16.9.2986","article-title":"Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms","volume":"16","author":"Senderowicz","year":"1998","journal-title":"J Clin Oncol"},{"key":"R39-6-20210128","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.2001.19.7.1985","article-title":"Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma","volume":"19","author":"Schwartz","year":"2001","journal-title":"J Clin Oncol"},{"key":"R40-6-20210128","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2002.08.080","article-title":"Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors","volume":"20","author":"Schwartz","year":"2002","journal-title":"J Clin Oncol"},{"key":"R41-6-20210128","first-page":"1590","article-title":"A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV nonsmall cell lung cancer","volume":"7","author":"Shapiro","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R42-6-20210128","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.2000.18.2.371","article-title":"Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago phase II consortium study","volume":"18","author":"Stadler","year":"2000","journal-title":"J Clin Oncol"},{"key":"R43-6-20210128","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/10428190290016908","article-title":"Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma","volume":"43","author":"Lin","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R44-6-20210128","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","article-title":"Flavopiridol administered as a 24-h continuous infusion in chronic lymphocytic leukemia lacks clinical activity","volume":"29","author":"Flinn","year":"2005","journal-title":"Leuk Res"},{"key":"R45-6-20210128","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1158\/1078-0432.CCR-04-2276","article-title":"Treatment of relapsed chronic lymphocytic leukemia by 72-h continuous infusion or 1-h bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805","volume":"11","author":"Byrd","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R46-6-20210128","first-page":"2482","article-title":"Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts","volume":"91","author":"Arguello","year":"1998","journal-title":"Blood"},{"key":"R47-6-20210128","first-page":"3400","article-title":"Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea","volume":"6","author":"Innocenti","year":"2000","journal-title":"Clin Cancer Res"},{"key":"R48-6-20210128","first-page":"294b","article-title":"Flavopiridol sensitivity of chronic lymphocytic leukemia (CLL) cells in vitro varies based upon species specific drug protein binding","volume":"96","author":"Shinn","year":"2000","journal-title":"Blood"},{"key":"R49-6-20210128","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"R50-6-20210128","doi-asserted-by":"crossref","first-page":"93a","DOI":"10.1182\/blood.V108.11.302.302","article-title":"Flavopiridol is active in genetically high-risk, relapsed chronic lymphocytic leukemia (CLL): analysis of 56 patients by cytogenetic abnormality","volume":"108","author":"Lin","year":"2006","journal-title":"Blood"},{"key":"R51-6-20210128","doi-asserted-by":"crossref","first-page":"805a","DOI":"10.1182\/blood.V108.11.2845.2845","article-title":"Flavopiridol can be safely dose escalated in relapsed CLL patients: achievement of target C max results in improved clinical activity","volume":"108","author":"Lin","year":"2006","journal-title":"Blood"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e3282efb9da","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:41:31Z","timestamp":1786038091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200711000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e3282efb9da","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}